Identification of causative variants in TXNL4A in Burn-McKeown Syndrome and isolated choanal atresia by Goos, JAC et al.
ARTICLE
Identiﬁcation of causative variants in TXNL4A in
Burn-McKeown syndrome and isolated choanal atresia
Jacqueline AC Goos*,1, Sigrid MA Swagemakers2,11, Stephen RF Twigg3,11, Marieke F van Dooren4,
A Jeannette M Hoogeboom4, Christian Beetz5, Sven Günther5, Frank J Magielsen4, Charlotte W Ockeloen6,
Maria A Ramos-Arroyo7, Rolph Pfundt6, Helger G Yntema6, Peter J van der Spek3, Philip Stanier8,
Dagmar Wieczorek9, Andrew OM Wilkie3, Ans MW van den Ouweland4, Irene MJ Mathijssen1
and Jane A Hurst10
Burn-McKeown syndrome (BMKS) is a rare syndrome characterized by choanal atresia, prominent ears, abnormalities of the
outer third of the lower eyelid, structural cardiac abnormalities, conductive and sensorineural hearing loss, and cleft lip.
Recently, causative compound heterozygous variants were identiﬁed in TXNL4A. We analyzed an individual with clinical features
of BMKS and her parents by whole-genome sequencing and identiﬁed compound heterozygous variants in TXNL4A (a novel
splice site variant (c.258-2A4G, (p.?)) and a 34 bp promoter deletion (hg19 chr18:g.77748581_77748614del (type 1Δ) in the
proband). Subsequently, we tested a cohort of 19 individuals with (mild) features of BMKS and 17 individuals with isolated
choanal atresia for causative variants in TXNL4A by dideoxy-sequence analysis. In one individual with BMKS unrelated to the
ﬁrst family, we identiﬁed the identical compound heterozygous variants. In an individual with isolated choanal atresia, we found
homozygosity for the same type 1Δ promoter deletion, whilst in two cousins from a family with choanal atresia and other minor
anomalies we found homozygosity for a different deletion within the promoter (hg19 chr18: g.77748604_77748637del (type
2Δ)). Hence, we identiﬁed causative recessive variants in TXNL4A in two individuals with BMKS as well as in three individuals
(from two families) with isolated choanal atresia.
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INTRODUCTION
Burn-McKeown syndrome (BMKS) was ﬁrst described in ﬁve children
by Burn et al.1 It is a rare disorder characterized by choanal atresia,
prominent ears, hypertelorism with short palpebral ﬁssures and
abnormalities of the outer third of the lower eyelids. Other features
that can be observed are structural cardiac abnormalities, conductive
and sensorineural hearing loss, and unilateral cleft lip.1 There is
clinical overlap with both Treacher Collins and CHARGE syndromes.
Burn et al1 advised counseling a high recurrence risk in families
with BMKS, but the inheritance pattern remained unclear until
recently. As the syndrome was repeatedly described in siblings and
mainly in males, an autosomal recessive1 or X-linked inheritance
pattern was suggested.2 However, the identiﬁcation of a chromosomal
rearrangement, 46,XX,r(18)(p14q23), in an isolated female case with
features of BMKS suggested terminal 18p or 18q as the locus for the
disorder.1 This was borne out by the detection of causative compound
heterozygous variants in TXNL4A (located on chromosome 18q23),
identiﬁed more than 20 years after the initial description of BMKS.3
TXNL4A is a member of the U5 spliceosomal complex that is
critical for pre-mRNA splicing.4 It has been suggested that reduced
expression of TXNL4A inﬂuences the splicing of a speciﬁc subset of
pre-mRNAs, resulting in the tissue-speciﬁc phenotypic spectrum of
BMKS.3,5 In the present study, we describe new causative variants in
TXNL4A and expand the associated phenotypic spectrum.
SUBJECTS AND METHODS
Subjects
Ethical approval from the board of the Medical Ethical Committee of the
Erasmus MC, University Medical Center Rotterdam, the Netherlands, was
given for whole-genome sequencing (WGS; MEC-2012-140) and for retro-
spective data collection (MEC-2013-547). UK samples were collected following
approval from the Great Ormond Street Hospital for Children NHS Trust
Ethics Committee (REC No. 08H0713/46). Informed consent was received
from the individuals and parents.
WGS was performed on DNA of the members of family 1 (see Figure 1).
To identify further mutation-positive individuals, dideoxy-sequence analysis
of the promoter region, the exons and the exon/intron boundaries of TXNL4A
was performed using DNA of 19 individuals who have clinical features that
overlap with (mild) BMKS. In addition, 17 individuals with isolated choanal
atresia were also tested for mutations in TXNL4A. In addition, 29 of the DNA
samples were analyzed for copy number variations in TXNL4A using a
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multiplex ligation-dependent probe ampliﬁcation (MLPA) assay as described by
Wieczorek et al.3
The variants identiﬁed were described according to HGVS nomenclature,6
using the reference sequences NM_006701.2, ENST00000269601 and
ENSG00000141759, on GRCh37/hg19 and were submitted to the Leiden Open
Variation Database (http://www.lovd.nl/TXNL4A).
Whole-genome sequencing
Before publication of the paper of Wieczorek et al,3 WGS was performed on
DNA of the proband of family 1 (III.2) and her parents (see Figure 1) by
Complete Genomics, a BGI company (Mountain View, CA, USA) as described
by Drmanac.7 Variants were annotated using NCBI build 36.3/hg18 and dbSNP
build 130. Data were analyzed using cga tools version 1.6.0.43 and TIBCO
Spotﬁre 7.0.0 (TIBCO Software Inc., Boston, MA, USA). The annotations were
converted to GRCh37/hg19 by using Human BLAT search on the UCSC
website (Kent Informatics, Inc., Santa Cruz, CA, USA) as described previously.8
An autosomal dominant disease model was tested in family 1. The analysis
was restricted to novel non-synonymous variants, variants disrupting a splice
site (± two bp), and insertions or deletions in the coding sequence (±50 bp).
The remaining variants were analyzed with Annovar,9 to get an indication of
the pathogenicity and the ESP frequency as given in Exome Variant Server
(EVS, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: http://
evs.gs.washington.edu/EVS/) [April 2014 accessed]). We focused on variants
that were located in genes without loss-of-function mutations in EVS.
Conﬁrmation by dideoxy-sequence analysis
The variants identiﬁed by WGS were validated by dideoxy-sequence analysis (all
primer sequences are provided in Supplementary Table 1). Ampliﬁcation
reactions were performed according to standard procedures. PCR products
were puriﬁed using Agencourt AMPure (Agencourt, Beckman Coulter Inc.,
Brea, CA, USA). Direct sequencing of both strands was performed using Big
Dye terminator version 3.1 (Applied Biosystems, Foster City, CA, USA) as
recommended by the manufacturer. Dye terminators were removed using
Agencourt CleanSeQ (Agencourt) and loaded on an ABI 3130XL Genetic
Analyzer (Applied Biosystems). The sequences were analyzed using SeqPilot
version 4.1.2 build 507 (JSI Medical Systems Gmbh, Kippenheim, Germany).
Conﬁrmation of effect of the variants on RNA expression
To analyze the effect of the variants on RNA expression, cDNA was analyzed by
restriction enzyme digestion and deep sequencing. First, RNA was extracted
according to the manufacturer’s protocol from venous blood collected into
PAXgene Blood RNA tubes (Qiagen N.V., Venlo, The Netherlands) from
individuals II.1, II.2 and III.2 (Figure 1, family 1). cDNA was synthesized using
the RevertAid First Strand cDNA kit (Thermo Scientiﬁc Inc., Waltham, MA,
USA), with random hexamer primers according to the manufacturer’s
instructions. Primers were designed for all exons and intron two to screen
for truncations and intron retention (Supplementary Table 1). cDNA was
ampliﬁed and products were electrophoresed on agarose gels and DNA was
visualized by staining with ethidium bromide (EtBr).
Figure 1 Pedigrees of families. Symbol deﬁnitions: not affected, BMKS, lagophtalmos, choanal atresia, prognathism and
maxillary hypoplasia. 1Δ, promoter deletion type 1Δ (hg19 chr18:g.77748581_77748614del), 2Δ, promoter deletion type 2Δ (hg19 chr18:
g.77748604_77748637del); NA, not available; Spl, splice site variant, − /− , no causative variant in TXNL4A.
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Digestion with PshAI and AhdI and electrophoresis of digests
To assess the effect of the paternal variant on RNA expression in family 1,
cDNA ampliﬁcation products were digested with PshAI or AhdI (New England
Biolabs Inc., Ipswich, MA, USA) and analyzed by agarose gel electrophoresis.
The forward primer was mutated to allow digestion with AhdI (underlined and
bold ‘a’ in Supplementary Table 1).
Deep sequencing by Ion PGM Sequencing
To distinguish between the wild-type and mutant allele, two heterozygous SNPs
in the 3'-UTR of TXNL4A that were identiﬁed in the WGS data from the
parents of the family 1 proband were used. To quantify the effect of the
maternal variant, deep sequencing covering the SNP was performed on cDNA
of the proband. Primers are given in Supplementary Table 1. The cDNA
ampliﬁcation products were diluted 1/100 and 2 μl was used in a second round
PCR, with a reverse primer including the Ion PGM P1 adapter, and a forward
primer with the Ion PGM A adapter sequence and a barcode sequence (reaction
conditions available on request). Ampliﬁcation products (roughly equal
amounts as judged by EtBr staining by agarose gel electrophoresis) were
combined and then puriﬁed with AMPure beads (Beckman Coulter). Emulsion
PCR and enrichment was performed with the Ion PGM Template OT2 200 Kit
(Life Technologies) according to the manufacturer’s instructions. Sequencing
of enriched templates was performed on the Ion Torrent PGM
(Life Technologies) for 125 cycles using the Ion PGM Sequencing 200 kit v2
and Ion 316 chips. Data were processed with Ion Torrent platform-speciﬁc
pipeline software v4.2.1.
RESULTS
Whole-genome sequencing of family 1
The proband of family 1 and her parents were analyzed by WGS.
Variants remaining after the various ﬁltering steps are available on
request. By testing the expected autosomal dominant disease model,
we identiﬁed a novel splice site variant upstream of the last exon in
TXNL4A (c.258-2A4G, (p.?)), that was inherited from the father.
According to both cga tools and ANNOVAR, the splice site variant
was predicted to be deleterious. As this variant was present in the
3′ splice site consensus sequence, it was highly conserved with a
PhyloP score of 1.824× 10− 5. The variant was not present in ESP,
1000 Genomes (The 1000 Genomes Project Consortium, 2012, URL:
http://www.1000genomes.org/10), Ensembl,11 nor in our in-house
Huvariome database.12 However, it did have an allele frequency of
7.31× 10− 6 in gnomAD.13 During the analysis, the phenotype was
recognized as suspected BMKS. Therefore, recessive variants on
chromosome 18 were implicated and the DNA sequence of TXNL4A
was scrutinized manually. Based on the publication of Wieczorek
et al,3 the likely signiﬁcance of a 34 bp deletion within the promoter
became apparent (hg19 chr18:g.77748581_77748614del, referred to as
type 1Δ and inherited from the mother).3 The presence of both
variants was conﬁrmed by dideoxy sequencing (Figure 2).
cDNA analysis of TXNL4A
RT-PCR analysis of the proband of family 1 and her parents, followed
by agarose gel electrophoresis, did not show any aberrantly spliced
products in any of the samples, despite the presence of the predicted
splice site variant in both the proband and her father. WGS data
indicated that both parents each carried a different sequence change
within the 3′ UTR of TXNL4A that was not inherited by their daughter
(thus located on the reference alleles): the father was heterozygous for
hg19 chr18:g.77733297dupC (rs77355432, dbSNP build 146) and the
mother for hg19 chr18:g.77733273C4T (rs4798931). Primers were
designed to amplify both SNPs in one amplicon.
The effect of the 3′ acceptor variant c.258-2A4G on splicing, was
assessed using the restriction enzymes AhdI and PshAI. AhdI was
speciﬁc for the 3′ UTR dupC (reference allele, not passed to the
proband), while PshAI was speciﬁc for the mutant allele in cDNA
from the father (passed to the proband). The primer was designed to
amplify the alleles equally, had they both been present in the cDNA.
Using AhdI, the cDNA of the father was digested almost to completion
(Figure 3), and using PshAI the cDNA remained undigested (data not
shown), indicating that there was no or extremely reduced mature
transcript from the mutant allele.
Deep sequencing of maternal cDNA demonstrated reduced expres-
sion from the allele with the type 1Δ: in a total of 36 924 reads, 8 636
reads (23%) were of the reference C (the allele with the promoter
variant), and 28 283 reads (77%) contained the variant T (wildtype
promoter allele).
Expansion of the mutation spectrum
Dideoxy sequencing of TXNL4A was performed on DNA obtained
from 19 index cases with (mild) features of BMKS. The proband of
family 2 (Figure 1, III.1 of family 2) was found to carry the identical
variants to those of the family 1 proband. Analysis of parental samples
showed that they were present in compound heterozygous state with
Figure 2 Electropherograms of dideoxy-sequence analyses. Red line indicates the start of the deletion. (a) control DNA. (b) splice site variant in DNA of III.2
of family 1. (c) region of type 1Δ deletion in control DNA. (d) heterozygous type 1Δ deletion in DNA of III.2 of family 1. (e) homozygous type 1Δ deletion as
seen in DNA of III.1 of family 3. (f) region of type 2Δ deletion in control DNA. (g) heterozygous type 2Δ deletion as seen in DNA of IV.6 of family 4. (h)
homozygous type 2Δ deletion as seen in DNA of V.4 of family 4.
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the type 1Δ deletion inherited from the father and the splice site
variant inherited from the mother. In addition, 17 index cases with
choanal atresia were tested for mutations in TXNL4A. In two
probands, homozygosity for a promoter deletion was identiﬁed. The
proband of family 3 (Figure 1, III.1 of family 3) had a uniparental
disomy of chromosome 18p11.32q23, leading to homozygosity for the
type 1Δ deletion. The family 4 proband (Figure 1, V.4 of family 4) was
homozygous for a slightly different promoter deletion: hg19 chr18:
g.77748604_77748637del corresponding to type 2Δ in Wieczorek
et al.3 The same genotype was also present in his ﬁrst cousin
(Figure 1, V.6 of family 4).
MLPA analysis was performed on the 29 samples with sufﬁcient
DNA available. This included samples of both families 3 and 4
(Table 2). Large rearrangements were not identiﬁed in any of these
samples.
Subjects
Nineteen individuals with clinical features overlapping with BMKS
syndrome and 17 individuals with isolated choanal atresia were tested
for mutations in TXNL4A. Causative variants were identiﬁed in ﬁve
individuals. An overview of the clinical phenotype of these individuals
is given in Table 1. The proband of family 4 and his ﬁrst cousin
(Figure 1, V.4 and V.6 of family 4) were previously described as
patients 1 and 3 in the paper of Ramos-Arroyo et al.14 All individuals
had choanal atresia and normal development. In three out of ﬁve,
their pregnancy was complicated by polyhydramnios. The same three
had a prominent nasal bridge. Maxillary hypoplasia was also seen in
the same three individuals, and micrognathia was seen in two out of
them. Two out of ﬁve individuals had defects of the lower eyelids. The
proband of family 4 and his ﬁrst cousin had oligodontia, however, due
to the high prevalence of this condition,15 we cannot rule out that this
is a separate condition that is segregating within this family.14
DISCUSSION
In two out of 20 unrelated individuals with clinical features of BMKS,
we identiﬁed compound heterozygosity in TXNL4A for a novel splice
site variant, c.258-2A4G, (p.?) and the type 1Δ promoter variant,
hg19 chr18:g.77748581_77748614del. Our ﬁndings support the idea
that causative TXNL4A variants do not completely ablate function in
BMKS.3
In nine out of 11 affected families, Wieczorek et al3 found a rare
loss-of-function variant (nonsense, frameshift or microdeletion) on
one allele in conjunction with a promoter deletion on the other allele.
In our deep sequencing analysis of RNA isolated from blood,
expression of the type 1Δ mutant allele was reduced by ~ 69%. This
is in keeping with a luciferase reporter gene assay, where the promoter
activity of constructs containing type 1Δ deletion was reduced by 59%
compared to a wild-type construct.3 The presence of the splice-site
variant on the other TXNL4A allele of the family 1 proband most
likely leads to loss-of-function, since analysis of paternal cDNA based
on the closely adjacent SNP rs77355432, indicated no evidence of
transcription of this allele (Figure 3). Wieczorek et al3 have shown that
deletion of exon three combined with type 1Δ causes BMKS. Hence,
we can conclude that the variants identiﬁed in the probands of families
1 and 2 are the underlying causes of the clinical phenotype.
In the paper of Wieczorek et al3 the allele frequency of the promoter
deletions in German control samples was estimated at 0.76%. A single
homozygous type 1Δ deletion was identiﬁed in 3343 population-based
German and South Asian samples. Unfortunately, data about the
craniofacial phenotype in that individual were not available. In this
study, we sequenced a cohort of 17 individuals with choanal atresia
and also identiﬁed a homozygous type 1Δ deletion (family 3).
Although the predicted frequency of homozygous type 1Δ deletions
was estimated at 1:17 300, which seemed to exclude this genotype as a
cause for BMKS, Wieczorek et al3 stated that this genotype might lead
to a mild phenotype. It seems likely that the isolated bilateral choanal
atresia identiﬁed in the proband of family 3 might be part of this mild
phenotype, especially since choanal atresia is one of the major
anomalies of BMKS. As isolated choanal atresia is a feature of the
Tbx22 knock-out mouse,16 the individuals with isolated choanal
atresia were screened for mutations in TBX22, but causative variants
were not found.
In family 4, homozygosity for the pathogenic promoter variant type
2Δ was found to segregate in the affected individuals. Wieczorek et al3
also found a homozygous type 2Δ case in an individual with true
BMKS and showed that promoter activity of a construct containing
type 2Δ was reduced by 72% compared to wild-type, indicating a
stronger reduction of TXNL4A expression than type 1Δ. However,
individuals with the type 2Δ (family 4) seem to be less severely affected
than the compound heterozygotes; only choanal atresia, hypodontia
and some minor anomalies were seen (Table 2). Further screening of
family 4 identiﬁed eight members who were heterozygous for type 2Δ,
and interestingly minor anomalies were present in two of them
(Figure 1 and Table 2). Our data support the proposed dosage-speciﬁc
effect.3,5
Wieczorek et al3 identiﬁed causative variants in nine out of 11
families, compared to two out of 18 in this study. This may be
attributed to the fact that in this work individuals were included with
only mild features of BMKS and may overlap with other conditions
such as bilateral craniofacial microsomia, CHARGE phenotype, and
asymmetrical Treacher-Collins like phenotype. Recently, it has been
shown that ribosomopathies, such as Treacher Collins syndrome, and
spliceosomopathies can have similar craniofacial phenotypes.5 In
contrast to CHARGE and Treacher Collins syndrome, individuals
with BMKS tend to have a normal intellectual development, however,
there is otherwise signiﬁcant clinical overlap. Therefore, we suggest it
will be important to test for mutations in TXNL4A if the clinical
phenotype is indicative of BMKS, but also if the clinical phenotype is
Figure 3 Restriction enzyme digest analysis of rs77355432 SNP in cDNA
from family 1; expected fragment sizes reference allele 249 bp (WT),
alternative allele 215+34 bp (dupC). Lane 1, uncut DNA. Lane 2, cDNA
from the proband is not digested with AhdI. Lane 3, cDNA of the father is
cut almost to completion with AhdI. Lane 4, cDNA of the mother is uncut
with AhdI. Lane 5, negative control.
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indicative of these other conditions should their appropriate gene tests
report negative.
CONCLUSION
We describe the ﬁnding of the splice site variant c.258-2A4G,
combined with promoter deletion type 1Δ, in TXNL4A as the genetic
cause of BMKS in two unrelated individuals. Homozygosity for the
type 1Δ deletion was identiﬁed in a third individual with isolated
choanal atresia. Homozygosity for the type 2Δ deletion was identiﬁed
in a family with choanal atresia and other minor anomalies. These
results conﬁrm that variants affecting function of TXNL4A are the
cause of BMKS and possibly a cause of isolated choanal atresia,
underlining the tissue-speciﬁc nature of craniofacial disorders caused
by spliceosomal defects.5
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